Immix Biopharma Inc (IMMX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $657.09M
Last updated: Nov 17, 2026 at 4:33 PM ET
Immix Biopharma Inc (IMMX) Statistics
Immix Biopharma (IMMX) has a market cap of $657.09M and an enterprise value of $337.64M. Its share count is up 132.06% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 48.62% below the market cap, as cash exceeds debt.
| Market Cap | $657.09M |
|---|---|
| Enterprise Value | $337.64M |
| Latest price (Nov 17, 2026) | $7.20 |
Key Dates
The next earnings report is expected on Mar 23, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 23, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 71.02% over 52 weeks and trades 24.76% below its 50-day average.
| Beta (1Y) | 1.80 |
|---|---|
| 52-Week Change | +71.02% |
| 1-Month Change | -12.41% |
| 3-Month Change | -45.41% |
| 6-Month Change | -18.74% |
| Total Return (1Y) | +71.02% |
| Total Return (3Y CAGR) | +18.19% |
| Return vs SPY (1Y) | +57.85% |
| Max Drawdown (1Y) | -50.24% |
| Max Drawdown (3Y) | -81.57% |
| Sharpe Ratio (1Y) | 0.65 |
| Correlation with SPY (1Y) | 0.30 |
| 50-Day Average | $9.57 |
| 200-Day Average | $9.63 |
| 52-Week Range | $3.78 to $15.10 |
| RSI (14 Days) | 37.4 |
| Average Volume (20 Days) | 1.17M |
Financial Position
Current assets cover 33.72x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 33.72x |
|---|---|
| Quick Ratio | 33.72x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on invested capital is -14.91% over the last 12 months, against a 5-year average of -31.62%.
| Return on Equity (ROE) | -13.81% |
|---|---|
| Return on Assets (ROA) | -13.37% |
| Return on Invested Capital (ROIC) | -14.91% |
| ROE (5Y Average) | -97.65% |
| ROA (5Y Average) | -78.03% |
| ROIC (5Y Average) | -31.62% |
Scores
IMMX has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$90.63K |
| Operating Income | -$50.10M |
| Pretax Income | -$46.23M |
| Net Income | -$46.26M |
| Reported EPS (TTM) | -$0.83 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 96.85% of the $345.95M in total assets.
| Cash and Equivalents | $320.32M |
|---|---|
| Total Debt | $868.50K |
| Net Cash | $319.45M |
| Net Cash Per Share | $4.31 |
| Working Capital | $328.05M |
| Shareholder Equity | $335.06M |
| Book Value Per Share | $4.52 |
| Total Assets | $345.95M |
| Total Liabilities | $10.89M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $339.90K of capital spending, operating cash flow left -$45.24M of free cash flow.
| Operating Cash Flow | -$44.90M |
|---|---|
| Capital Expenditures | $339.90K |
| Free Cash Flow | -$45.24M |
| FCF Per Share | -$0.55 |
| Depreciation and Amortization | $467.86K |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | +72.49% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | +72.49% |
Dividends and Yields
IMMX does not pay a dividend. Its free cash flow yield is -8.48%.
| FCF Yield | -8.48% |
|---|---|
| Buyback Yield | -37.28% |
| Shareholder Yield | -37.28% |
Peer Position
Against 7 similar companies, IMMX has the 3rd highest ROIC.
ROICPeer median -53.81%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -68.20%
| ROIC | -14.91% vs -53.81% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -100.00% vs -68.20% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About IMMX
What is IMMX's market cap?
Immix Biopharma has a market cap of $657.09M. Its enterprise value, which adds debt and subtracts cash, is $337.64M.
How many shares of IMMX are outstanding?
Immix Biopharma has 74.09M shares outstanding. The count is up 132.06% from a year earlier.
Does IMMX pay a dividend?
No. Immix Biopharma does not pay a dividend.
How much debt does IMMX have?
Immix Biopharma has $868.50K of total debt and $320.32M of cash and equivalents, a net cash position of $319.45M.
IMMX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors